





I U I S I U U N S I D I N D U E D I N D E N I B E S I D

On May 7, 2024, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2024. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2024, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

I U E D N D E N S N S D S I N D U E E S I

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company dated May 7, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By: /s/ Adam Logal
Name: Adam Logal
Title: Senior Vice President, Chief Financial Officer

Date: May 7, 2024

, ,

“ ”@



OPKO Health, Inc. and Subsidiaries
 Condensed Consolidated Balance Sheets
 (in millions)
 Unaudited

	As of March 31, 2024	December 31, 2023
Assets:		
Cash and cash equivalents	\$ 75.6	\$ Ints

OPKO Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in millions, except share and per share data)
Unaudited

	For the three months ended	
	2024	2023
Revenues		
Revenue from services	\$ 126.9	\$ 132.4
Revenue from products	38.1	40.4
Revenue from transfer of intellectual property	8.7	64.8
Total revenues	<u>173.7</u>	<u>237.6</u>
Costs and expenses		
Cost of service revenues	109.9	114.1
Cost of product revenues	21.8	24.2
Selling, general and administrative	70.2	75.7
Research and development	21.9	32.6
Contingent consideration	0.0	0.8
Amortization of intangible assets	21.4	21.5
Total costs and expenses	<u>245.2</u>	<u>268.2</u>
Operating loss	(71.5)	(30.6)
Other income and (expense), net	(11.7)	13.6
Loss before income taxes and investment losses	<u>(83.2)</u>	<u>(17.0)</u>
Income tax benefit (provision)	1.4	(1.2)
Net loss before investment losses	<u>(81.8)</u>	<u>(18.2)</u>
Loss from investments in investe		
	<u><u> </u></u>	<u><u> </u></u>
	<u><u> </u></u>	<u><u> </u></u>